Investment analysts at Robert W. Baird initiated coverage on shares of GTx, Inc. (NASDAQ:GTXI) in a report released on Tuesday, StockTargetPrices.com reports. The brokerage set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s price target points to a potential upside of 52.88% from the stock’s current price.

Separately, Stifel Nicolaus assumed coverage on shares of GTx in a research report on Thursday, November 9th. They set a “buy” rating on the stock.

GTx (NASDAQ:GTXI) opened at $11.12 on Tuesday. GTx has a 1 year low of $2.73 and a 1 year high of $12.96.

GTx (NASDAQ:GTXI) last issued its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). sell-side analysts expect that GTx will post -1.48 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/21/gtx-inc-gtxi-coverage-initiated-by-analysts-at-robert-w-baird.html.

A number of large investors have recently added to or reduced their stakes in the stock. Caxton Corp bought a new position in GTx during the third quarter worth about $531,000. Abingworth LLP bought a new position in GTx during the third quarter worth about $2,781,000. Finally, Bank of New York Mellon Corp bought a new position in GTx during the second quarter worth about $124,000. 9.02% of the stock is currently owned by institutional investors and hedge funds.

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Stock Target Prices

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.